Valion Bio, Inc. (VBIO)
VBIO moved a median of 0.00% 30 minutes after news, and -4.66% by the close. How VBIO actually reacts to news — the realized, point-in-time move the market made, measured across 49 labeled events over the last three years with zero look-ahead.
VBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -1.32% | 26% | 47 |
| 30-min | 0.00% | 49% | 47 |
| 60-min | -1.33% | 35% | 49 |
| to close | -4.66% | 33% | 49 |
| Middle 50% of VBIO reactions | -4.35% to +2.71% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 49 |
Half of all Valion Bio, Inc. news events land between -4.35% and +2.71% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VBIO's baseline. Nothing else.
Recent VBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A Valion Bio, Inc. For: Nov 12 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form S-3 Valion Bio, Inc. | SEC filing · Form S-3 | SEC EDGAR | — | — | |
| Form 8-K Valion Bio, Inc. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +1.80% | +10.81% | |
| Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone | Press release | ACCESS Newswire | +1.80% | +10.81% | |
| Form 8-K Valion Bio, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | -5.84% | |
| With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge | Press release | ACCESS Newswire | -1.86% | -5.84% | |
| Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers | Press release | ACCESS Newswire | -0.46% | -2.28% | |
| Form 8-K Valion Bio, Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +3.87% | +6.76% | |
| Form S-3 Valion Bio, Inc. | SEC filing · Form S-3 | SEC EDGAR | +3.87% | +6.76% | |
| Form 8-K Valion Bio, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.85% | |
| Form PRE 14A Valion Bio, Inc. For: Oct 02 | SEC filing · Form PRE | SEC EDGAR | -2.46% | +2.48% | |
| New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod | Press release | ACCESS Newswire | +2.17% | +2.48% | |
| Form 8-K Valion Bio, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | -1.57% | |
| Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity | Press release | ACCESS Newswire | -10.30% | -29.65% | |
| Form 8-K Valion Bio, Inc. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -1.31% | +11.43% | |
| Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions | Press release | ACCESS Newswire | -1.31% | +11.43% | |
| Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule | Press release | ACCESS Newswire | +0.41% | +3.32% | |
| Form 8-K Valion Bio, Inc. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | -4.66% | |
| Valion Bio Announces Changes to Management and Board of Directors | Press release | ACCESS Newswire | +1.61% | -4.66% | |
| Form 8-K Valion Bio, Inc. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -3.09% | -19.29% | |
| Valion Bio Announces Reverse Stock Split | Press release | ACCESS Newswire | -3.09% | -19.29% | |
| Form RW Valion Bio, Inc. | SEC filing · Form RW | SEC EDGAR | +0.75% | +38.33% | |
| Form 8-K/A Valion Bio, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.17% | |
| Form 8-K Valion Bio, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | +5.31% | |
| Form 10-Q Valion Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.90% | +5.31% | |
| Form EFFECT Valion Bio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +6.25% | +6.75% | |
| Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase | Press release | ACCESS Newswire | +1.41% | -1.61% | |
| Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury | Press release | ACCESS Newswire | +48.65% | -38.92% | |
| Form 8-K Valion Bio, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +4.42% | +0.88% | |
| Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway | Press release | PR Newswire | -5.04% | -8.45% | |
| World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market | Press release | PR Newswire | +0.16% | -12.98% | |
| Form DEF 14A Valion Bio, Inc. For: Aug 14 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -20.81% | |
| Form S-1 Valion Bio, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -20.81% | |
| Form 8-K Valion Bio, Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | -4.63% | |
| Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion | Press release | PR Newswire | -0.41% | -4.63% | |
| Form PRE 14A Valion Bio, Inc. For: Aug 14 | SEC filing · Form PRE | SEC EDGAR | +0.30% | -3.33% | |
| AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS | Press release | PR Newswire | +1.47% | +19.57% | |
| Form 8-K Valion Bio, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -8.68% | |
| Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures | Press release | PR Newswire | -3.17% | -4.79% | |
| Form S-8 Valion Bio, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +6.25% | |
| Form 8-K Valion Bio, Inc. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -4.48% | -3.73% | |
| VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | Press release | PR Newswire | -3.14% | +4.45% | |
| Form 10-Q Valion Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.09% | -9.28% | |
| Form 8-K Valion Bio, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -3.09% | -9.28% | |
| VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS | Press release | PR Newswire | -3.09% | -9.28% | |
| Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform | Press release | PR Newswire | -3.09% | -9.28% | |
| Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | PR Newswire | -1.32% | +16.84% | |
| Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™ | Press release | PR Newswire | -3.73% | +3.83% | |
| VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION | Press release | PR Newswire | -6.60% | -4.72% | |
| Valion Bio Appoints Melinda Lackey as General Counsel | Press release | PR Newswire | -6.60% | -4.72% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VBIO section they belong to.
Where else VBIO is measured.
VBIO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VITROLIFE AB UNSP/ADR (VTRLY) | 50 | 0.00% | 0% |
| Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) | 49 | -0.01% | 17% |
| Advaxis, Inc. (ADXS) | 48 | 0.00% | 21% |
| Arch Biopartners Inc (ARCH_CDNX) | 48 | -0.59% | 19% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Valion Bio, Inc.'s median reaction calculated?
Every labeled VBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 49 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of VBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.